General Information of Drug (ID: DM30WDL)

Drug Name
SYM2081 Drug Info
Synonyms KRKRAOXTGDJWNI-DMTCNVIQSA-L; (2S,4R)-2-amino-4-methylpentanedioate; [3H](2S,4R)-4-methylglutamate; [3H]SYM2081; [(3)H]4MG; (2S,4R)-Me-Glu; GTPL4317; GTPL4075; compound 52 [PMID:
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1] , [2]
Cross-matching ID
PubChem CID
21117106
TTD Drug ID
DM30WDL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
[3H]kainate DMMK7XU Discovery agent N.A. Investigative [7]
dysiherbaine DM0EBAF Discovery agent N.A. Investigative [7]
domoic acid DMYPVO0 Discovery agent N.A. Investigative [7]
2,4-epi-neodysiherbaine DMZRY0Q Discovery agent N.A. Investigative [7]
Drug Name Drug ID Indication ICD 11 Highest Status REF
[3H]kainate DMMK7XU Discovery agent N.A. Investigative [8]
dysiherbaine DM0EBAF Discovery agent N.A. Investigative [8]
UBP310 DMVQL3J Discovery agent N.A. Investigative [11]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Topiramate DM82Z30 Alcohol dependence 6C40.2 Approved [12]
LY293558 DM4N6EK Pain MG30-MG3Z Phase 2 [13]
NS 1209 DM9EFH0 Epilepsy 8A60-8A68 Phase 2 [14]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [15]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [15]
[3H]kainate DMMK7XU Discovery agent N.A. Investigative [6]
[3H]quisqualate DMDQBTX Discovery agent N.A. Investigative [16]
DNQX DMQXPA5 Discovery agent N.A. Investigative [17]
dysiherbaine DM0EBAF Discovery agent N.A. Investigative [6]
domoic acid DMYPVO0 Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
D-aspartic acid DM7Z892 Discovery agent N.A. Investigative [3]
[3H]ETB-TBOA DMWGY61 Discovery agent N.A. Investigative [18]
DL-TBOA DM2HGNU Discovery agent N.A. Investigative [19]
UCPH-101 DMTQEDA Discovery agent N.A. Investigative [20]
Drug Name Drug ID Indication ICD 11 Highest Status REF
[3H]kainate DMMK7XU Discovery agent N.A. Investigative [9]
dysiherbaine DM0EBAF Discovery agent N.A. Investigative [9]
domoic acid DMYPVO0 Discovery agent N.A. Investigative [9]
Drug Name Drug ID Indication ICD 11 Highest Status REF
[3H]kainate DMMK7XU Discovery agent N.A. Investigative [10]
dysiherbaine DM0EBAF Discovery agent N.A. Investigative [10]
domoic acid DMYPVO0 Discovery agent N.A. Investigative [10]
Drug Name Drug ID Indication ICD 11 Highest Status REF
D-aspartic acid DM7Z892 Discovery agent N.A. Investigative [5]
[3H]ETB-TBOA DMWGY61 Discovery agent N.A. Investigative [18]
DL-TBOA DM2HGNU Discovery agent N.A. Investigative [19]
Threo-3-methylglutamate DMOE3IJ Discovery agent N.A. Investigative [4]
WAY-213613 DMMXL4E Discovery agent N.A. Investigative [21]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Excitatory amino acid transporter 1 (SLC1A3) TT8WRDA EAA1_HUMAN Modulator [3]
Excitatory amino acid transporter 2 (SLC1A2) TT2F078 EAA2_HUMAN Inhibitor [4] , [5]
Glutamate receptor ionotropic kainate 1 (GRIK1) TT0MYE2 GRIK1_HUMAN Agonist [6]
Glutamate receptor ionotropic kainate 2 (GRIK2) TT0K5RG GRIK2_HUMAN Agonist [7]
Glutamate receptor ionotropic kainate 3 (GluK3) TTNP6O2 GRIK3_HUMAN Agonist [8]
Glutamate receptor ionotropic kainate 4 (GluK4) TTQV6BO GRIK4_HUMAN Agonist [9]
Glutamate receptor ionotropic kainate 5 (GRIK5) TTO6LI7 GRIK5_HUMAN Agonist [10]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4075).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4317).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 868).
4 Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol Pharmacol. 1997 May;51(5):809-15.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 869).
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451).
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 452).
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 453).
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 454).
11 Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H]UBP310. Mol Pharmacol. 2010 Dec;78(6):1036-45.
12 Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43.
13 Pharmacogenetics of new analgesics. Br J Pharmacol. 2011 Jun;163(3):447-60.
14 The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg. 2009 Apr;108(4):1311-9.
15 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
16 Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103.
17 Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
18 Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302.
19 DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201.
20 Discovery of the first selective inhibitor of excitatory amino acid transporter subtype 1. J Med Chem. 2009 Feb 26;52(4):912-5.
21 Characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinit... Mol Pharmacol. 2005 Oct;68(4):974-82.